Transcatheter aortic valve replacement (TAVR) using the Evolut valve is projected to provide high economic value compared with surgical aortic valve replacement (SAVR) for low-risk patients, largely driven by improved survival, according to an updated cost-effectiveness analysis using new 4-year data.